A Study to Investigate CV Outcomes With Elecoglipron Compared With Placebo in Adult Participants With HFpEF or HFmrEF (NCT07761117)
A Phase III, Randomized, Double-blind, Parallel-group, Placebo-controlled, Multicenter Study to Evaluate the Effect of Elecoglipron in Reducing Cardiovascular Outcomes in Participants With HFpEF and HFmrEF (Elevate-HF)
🩺 Plain-English Summary (8th-Grade Level)
This is a Phase III, randomized, double-blind, parallel-group, placebo-controlled, multicenter study to investigate CV outcomes with elecoglipron compared with placebo, in adults with heart failure with preserved ejection fraction (HFpEF)/heart failure with mildly reduced ejection fraction (HFmrEF), irrespective of T2DM status, and who are on background dapagliflozin in addition to other background standard of care.
Who can join: Review the eligibility criteria below.
Location: Research Site — Fairhope, Alabama
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (366 Sites)
Showing the first 25 of 366 sites.
- Research Site — Fairhope, Alabama
- Research Site — Beverly Hills, California
- Research Site — Huntington Beach, California
- Research Site — Huntington Park, California
- Research Site — Loma Linda, California
- Research Site — Lomita, California
- Research Site — Northridge, California
- Research Site — Tarzana, California
- Research Site — New Haven, Connecticut
- Research Site — Hialeah, Florida
- Research Site — Jacksonville, Florida
- Research Site — Lakeland, Florida
- Research Site — Miami, Florida
- Research Site — Miami, Florida
- Research Site — Atlanta, Georgia
- Research Site — Columbus, Georgia
- Research Site — Tucker, Georgia
- Research Site — Champaign, Illinois
- Research Site — Park Ridge, Illinois
- Research Site — Schaumburg, Illinois
- Research Site — Indianapolis, Indiana
- Research Site — Waterloo, Iowa
- Research Site — Bossier City, Louisiana
- Research Site — Covington, Louisiana
- Research Site — Lafayette, Louisiana
📞 Contact the Study Coordinator
Phone: (877) 240-9479
Email: information.center@astrazeneca.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Heart Failure With Preserved Ejection Fraction (HFpEF)
- Flow Regulation by Opening the SepTum in Patients With Heart Failure; a Prospective, Randomized, Sham-controlled, Double-blind, Global Multicenter Study — Phoenix, Arizona
- Study in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF) — Chicago, Illinois
- ELEVATE-HFpEF Clinical Study — Phoenix, Arizona
- Hearts on Fire: Targeting Inflammation in Heart Failure With Preserved Ejection Fraction — Gainesville, Florida
Explore by condition: All Heart Failure With Preserved Ejection Fraction (HFpEF) clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.